Seribantumab

DB11857InvestigationalProtein Based Therapies

Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Code names: MM-121 · SAR-256212

Resolves to

Compound

UNII1N3L70MDFXCAS1334296-12-6

Targets

P21860ERBB3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Seribantumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account